Introduction {#s1}
============

The colon epithelium is constantly regenerated by stem cells residing at the bottoms of the intestinal crypts ([@bib36]). Infection of pathogenic bacteria in the colon can disrupt the normal gut microbiome and cause chronic inflammation, which has been linked to diseases including as inflammatory bowel disease (IBD) and recognized as a significant risk factor for colorectal cancer (CRC) development ([@bib29]; [@bib79]; [@bib22]). It has been estimated that chronic inflammation and persistent infections contribute to a significant portion of human cancers, especially CRC ([@bib79]; [@bib87]).

Inflammation plays a dual role in tissue homeostasis. On one hand, inflammation is associated with damage to the tissue; on the other hand, it triggers stem cell proliferation and reparative regeneration ([@bib38]). Events of damage and inflammation have been associated with regenerative signaling pathways such as Wnt to increase the number of stem cells and cause regeneration and hyperplasia in intestinal and colonic epithelia ([@bib5]; [@bib51]).

Inflammation triggers intestinal and colonic epithelial reparative regeneration via inflammatory cytokines, including TNF-a, IL-6, IL-17, and IL-22. These cytokines upregulate downstream pathways such as MAPK, JAK-STAT3, and NF-κB, which control processes including cell proliferation and differentiation ([@bib38]; [@bib19]; [@bib73]; [@bib72]; [@bib71]). Deficiency in IL-22 or IL-17 Receptor E (IL-17RE) led to enhanced mucosal damage after infection by pathogenic bacteria such as *Citrobacter rodentium* ([@bib71]; [@bib84]).

On the other hand, chronic inflammation causes excessive regeneration, and the resulting hyperplasia could eventually lead to cancer. TNF-α is associated with CRC progression ([@bib2]; [@bib86]), and blocking TNF-α reduces the likelihood of colorectal carcinogenesis associated with chronic colitis ([@bib56]). IL-17 have also been shown to promote colitis-associated early colorectal carcinogenesis ([@bib31]; [@bib78]), and IL-22 stimulates stem cell growth after injury and promotes CRC stemness ([@bib46]; [@bib43]). Infiltration of T helper 1 (Th1) cells in CRC tumor specimens is associated with prolonged disease-free survival. However, infiltration of T helper 17 (Th17) cells, which secrete IL-17 and IL-22, is predictive of poor prognosis for CRC patients ([@bib76]).

The microRNA *miR-34a* is an important tumor suppressor that targets pro-growth genes ([@bib32]; [@bib18]), and its mimics are among the first microRNA mimics to reach clinical trial for cancer therapy ([@bib13]; [@bib6]). *miR-34a* also limits self-renewal of cancer stem cells ([@bib14]; [@bib15]; [@bib47]). *miR-34a* expression is often silenced in various cancer types ([@bib48]; [@bib40]; [@bib25]), and methylation of the *miR-34a* promoter is correlated with CRC progression ([@bib69]; [@bib80]). Nevertheless, *miR-34a* deficiency alone does not increase susceptibility to spontaneous tumorigenesis ([@bib20]; [@bib37]; [@bib24]), raising many questions about the role of *miR-34a* in tissue homeostasis.

In this study, we demonstrate that *miR-34a* acts as safeguard to protect the stem cell niche during inflammation-induced reparative regeneration. *miR-34a* deficiency led to colon tumorigenesis after *C. rodentium* infection, where Th17 cell infiltration and epithelial stem cell proliferation were observed. During the pro-inflammatory response, *miR-34a* suppressed Th17 cell differentiation and expansion by targeting IL-23R, Th17 cell recruitment to the colon epithelium by targeting CCL22, and IL-17 induced stem cell proliferation by targeting IL-17RD. Loss of *miR-34a* results in a reparative regeneration process that goes awry.

Results {#s2}
=======

*C. rodentium* infection promotes colon carcinogenesis and stem cell enrichment in *miR-34a-/-* mice {#s2-1}
----------------------------------------------------------------------------------------------------

Microbial dysbiosis causes chronic inflammation associated with CRC ([@bib70]; [@bib16]; [@bib55]; [@bib75]). *C. Rodentium* is a mouse mucosal pathogen that shares pathogenic mechanisms and 67% of its genes with enteropathogenic *Escherichia coli* (EPEC) and enterohaemorrhagic *E. coli* (EHEC), which are two clinically important human gastrointestinal pathogens ([@bib64]; [@bib65]; [@bib54]; [@bib12]; [@bib11]; [@bib30]). *C. Rodentium* has been used as a model to study mucosal immunology, including intestinal inflammatory responses during bacteria-induced colitis and colon tumorigenesis ([@bib23]; [@bib17]; [@bib33]). *C. rodentium* infection increases the number of colonic adenomas in ApcMin mice but does not cause adenoma formation in wild-type mice ([@bib53]).

After *C. rodentium* (2 × 10^9^ CFU) infection, both wild-type and *miR-34a-/-* mice developed diarrhea and weight loss within 2 weeks. Elongation of crypts and loss of goblet cells were observed ([Figure 1A](#fig1){ref-type="fig"}). Histopathological changes of pre-neoplasia and neoplasia were limited to the *miR-34a-/-* genotype and were first noted at the four-month time point. Microscopic sections from wild type control mice were free of dysplastic and neoplastic changes at four-month and six-month time points following infection ([@bib10]). In *miR-34a-/-* mice, no dysplasia or early neoplasia was present at a two-month time point (0/4), whereas at four months half the animals (2/4) had dysplastic change microscopically. At the six-month time point, 11 out of 20 miR 34a-/- mice had microscopic changes ranging from dysplasia (2/20), to adenoma (7/20), to adenocarcinoma (2/20) ([Figure 1A--C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). All tumors in this model were relatively well differentiated. One animal with a colonic adenocarcinoma in the section of distal colon also had a squamous cell carcinoma of the rectum. Dysplastic and neoplastic changes were characterized by strong intracytoplasmic β-catenin staining and occasional cells with nuclear staining ([Figure 1A](#fig1){ref-type="fig"}). The earliest dysplastic changes are noted in deep reaches of crypts that are within inflamed ulcerated colonic mucosa in several of the sections where the diffuse inflammation of the *C. rodentium* has subsided and focal long-standing inflammation has set up due to ulceration of the surface. ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). No APC mutations were detected in the tumors from the infected *miR-34a-/-* mice ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). No liver or lung metastasis was found in the *C. rodentium-*infected mice ([Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}).

![*C.rodentium* infection induces colonic tumor formation and stem cell enrichment in *miR-34a-/-* mice.\
(**A**) Representative H and E staining of colon tissues from infected and uninfected wildtype (WT) and *miR-34a-/-* mice. Scale bar, 100 μm. (**B**) Representative images of mouse colons uninfected or infected with *C. rodentium*. The arrows indicate the visible colon tumors. 2 × 10^9^ CFU *C. rodentium* were used to infect the mice orally. Six months after the infection, the mice were euthanized and the colons were imaged. Scale bar, 5 mm. (**C**) Frequencies of colonic tumor formation in infected and uninfected mice. (**D**) Immunofluorescence of Ascl2 showing enriched colon stem cells in *miR-34a-/-* colon tumors. Scale bar, 40 μm. (**E**) Western blot of Ascl2 and Lgr5 showing enriched colon stem cells in miR-34a-/- colon tumors. (**F--H**) Representative colon organoids images (**F**) and quantification showing organoid-forming efficiency (**H**) and organoid sizes. Colon organoids were cultured from uninfected mice and *C. rodentium* infected mice after 2 months. 1000 organoid cells from each condition were reseeded to examine organoid-forming efficiency and organoids growth.](elife-39479-fig1){#fig1}

The colon stem cells, marked by the Wnt signaling enhancers Lgr5 and Ascl2 ([@bib67]), are usually confined at the base of the crypt in wild-type and *miR-34a-/-* mice but became enriched in *C. rodentium*-induced colon tumors in *miR-34a-/-* mice ([Figure 1D](#fig1){ref-type="fig"}). Enrichment of Lgr5 and Ascl2 expression in the colon tumors of infected *miR-34a-/-* mice was further confirmed by western blot ([Figure 1E](#fig1){ref-type="fig"}). Colonic epithelial cells from infected *miR-34a-/-* mice (2 months post infection) had significantly higher organoid-forming efficiency and growth rates that the other groups ([@bib62]; [@bib63]) ([Figure 1F--H](#fig1){ref-type="fig"}).

Th17 cells are enriched in number and in close proximity to stem cells in *miR-34a-/-* colon tumors {#s2-2}
---------------------------------------------------------------------------------------------------

CD4 +T helper (Th) cells are known to infiltrate and accumulate in the inflammatory environment, which can either promote or suppress tissue malignancy ([@bib74]; [@bib39]). We isolated CD4 +Th cells from the colon epithelium of *C. rodentium*-infected wild-type and *miR-34a-/-* mice and analyzed the relative abundance of Th1, Th2, Th17, and Treg subpopulations according to their associated expression of IFN-γ, IL-4, IL-17, and FoxP3, respectively. IFN-γ, IL-4, and FoxP3 levels were similar between wild-type and *miR-34a-/-* tissue, but IL-17 was significantly upregulated in *miR-34a-/-* tissue ([Figure 2A](#fig2){ref-type="fig"}). *miR-34a* deletion increased the number of CD4 +IL17+Th17 in the colon 2 and 6 months post *C. rodentium* infection ([Figure 2B,C](#fig2){ref-type="fig"}). Immunofluorescence suggested that many of the enriched CD4 +IL-17 + Th17 cells were in proximity to Ascl2 +colon stem cells ([Figure 2D,E](#fig2){ref-type="fig"}).

![*C.rodentium* infection enhances Th17 cell infiltration in *miR-34a-/*- colonic tumors.\
(**A**) RT-qPCR showing relative expression of the CD4+ T lymphocyte genes associated with Th1 (*IFN-γ*), Th2 (*IL-4*), Th17 (IL-17), and Treg (FOXP3) cells in the colons from *C. rodentium* infected wild-type and *miR-34a-/-* mice. (**B**) FACS analysis showing Th17 cells (CD4+/IL-17+) numbers in infected and uninfected mice colon at month 2. (**C**) FACS analyses of CD4 +T cells from each infected and uninfected WT and *miR-34a-/-* mice colon at month 6. The percentages of Th17 cells (CD4+/IL-17+) are marked. (**D and E**) Immunofluorescence of CD4 (**D**) and IL-17 (**E**) in infected colons showing enhanced Th17 cells infiltrating in *miR-34a-/-* colonic tumors. Scale bar, 40 μm. Error bars denote s.d. of triplicates. \*\*\*p\<0.001. p-value was calculated based on Student's t-test.](elife-39479-fig2){#fig2}

In the infected colon, miR-34a deletion did not significantly increase the number or IL-17 expression level of lineage(CD3e/Ly-6G/Ly-6C/CD11b/CD45R/B220/TER-119)-/CD117+/CD45 +cells, which contain a subset of ILC3 cells that may express IL-17 ([@bib27]) ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). Nevertheless, more markers will be needed to distinguish ILC3 and its subtypes specifically. Similarly, the macrophage and neutrophil populations were only slightly affected ([Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}).

*miR-34a* suppresses Th17 differentiation and expansion by targeting IL6R and IL-23R {#s2-3}
------------------------------------------------------------------------------------

We then aimed to understand how *miR-34a* deletion led to accumulation of Th17 cells in the *C. rodentium*-induced colon tumors. IL-6 is critical for initiating the differentiation of native CD4 +T cells into Th17 cells, and IL-23 is essential for the final step of Th17 cell differentiation, its proliferation, and IL-17 expression ([@bib27]; [@bib1]; [@bib77]). We found that protein levels of IL-6R and IL-23R, the receptors for IL-6 and IL-23, were upregulated in CD4 +T cells isolated from the *miR-34a-/-* colon compared to the wild-type control ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). The RNA22 algorithm identified putative *miR-34a* binding sites in the *IL-6r* and *IL-23r* 3\`UTRs ([Figure 3B,C](#fig3){ref-type="fig"}), which were then confirmed by the luciferase reporter assay ([Figure 3D,E](#fig3){ref-type="fig"}).

![*miR-34a* targets IL-6R, IL-23R and CCL22.\
(**A**) Western blot showing IL-6R and IL-23R expression levels in CD4 +T cells isolated from *C. rodentium* infected colon of wild-type and *miR-34a-/-* mice. (**B and C**) Schematic representation of mouse *IL-6r* (**B**) and *IL-23r* (**C**) 3\`UTRs containing the putative *miR-34a* binding sites. (**D and E**) Luciferase reporter assays confirming the *miR-34a* binding sites. 3\`UTRs of mouse *IL-6r* (**D**) and *IL-23r* (**E**) containing wild-type (Wt) or mutated (Mut) putative *miR-34a* binding sites were cloned into the 3\`UTR of firefly luciferase (Fluc). Ectopic *miR-34a* expression in CT26 cells downregulated luciferase in Wt cells, but not in Mut cells. Fluc signals were normalized by a simultaneously delivered Renillar luciferase (Rluc) expression plasmid. (**F**) FACS showing knockdown of *IL-6r* or *IL-23r* in CD4 +T cells largely offsets the effect of *miR-34a* loss on Th17 cell differentiation. (**G**) Western blot showing increase of CCL22 expression in *miR-34a-/-* colon crypts. (**H**) Schematic representation of *miR-34a* binding site on the mouse *CCL22* 3\`UTR. (**I**) Luciferase reporter assays confirming the miR-34a binding sites in mouse *CCL22* 3\`UTR. (**J**) Chemotaxis assay showing knockdown of *CCL22* in colon tumor organoid cells or neutralization of CCL22 with anti-CCL22 antibody suppresses Th17 cell migration to colon tumor organoid conditioned medium. Error bars denote s.d. of triplicates. \*\*p\<0.01; \*\*\*p\<0.001. p-value was calculated based on Student's t-test.](elife-39479-fig3){#fig3}

To evaluate the *miR-34a*/IL-6R and *miR-34a*/IL-23R axes for Th17 cell differentiation, we performed an in vitro Th17 differentiation assay ([@bib28]) using CD4 +T cells isolated from the wild-type and *miR-34a-/-* mice. Loss of *miR-34a* significantly enhanced CD4 +T cell differentiation into Th17 cells, which was largely abrogated by knockdown of either *IL-6r* or *IL-23r* ([Figure 3F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Therefore, *miR-34a* suppresses Th17 cell differentiation by targeting IL-6R and IL-23R.

*miR-34a* suppresses Th17 recruitment by targeting CCL22 {#s2-4}
--------------------------------------------------------

Th17 cells express chemokine receptors CCR6 and CCR4 ([@bib4]), and the CCR6/CCL20 and CCR4/CCL22 axes play important roles in Th17 cell migration ([@bib12]). Loss of *miR-34a* did not affect *CCR6* or *CCR4* expression in CD4 +T cells ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). However, *CCL22* expression in the colon epithelium was significantly upregulated in the *miR-34a-/-* mice compared to the wild-type, while *CCL20* expression remained unchanged ([Figure 3G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). It has been previously reported that a TGF-β-*miR-34a*-CCL22 axis promotes venous metastases of HBV-positive liver cancer ([@bib82]). Our western blot and luciferase reporter assays confirmed that *miR-34a* suppressed *CCL22* by directly targeting its 3\`UTR in colon epithelial cells ([Figure 3G--I](#fig3){ref-type="fig"}).

Conditioned medium collected from *miR-34a-/-* colon tumor organoids enhanced the migration of *in vito*-differentiated Th17 cells in comparison to medium from the wild-type colon organoids ([Figure 3J](#fig3){ref-type="fig"}). The addition of anti-CCL22 neutralizing antibody in the medium or knockdown of *CCL22* in *miR-34a-/-* colon tumor organoids reduced Th17 migration back to the wild-type level ([Figure 3J](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Therefore, *miR-34a* suppresses recruitment of Th17 cells by targeting CCL22 production in colon epithelial cells.

Th17 cells promote colon organoid growth via IL-17 {#s2-5}
--------------------------------------------------

We then tested whether Th17 cells, which were enriched by loss of *miR-34a* and were located in proximity to Ascl2 +colon stem cells ([Figure 2B--D](#fig2){ref-type="fig"}), regulated colon epithelial cell proliferation. Mouse CD4 +T cells were induced to differentiate into Th17 cells and co-cultured with colon organoids. The presence of Th17 cells significantly increased the organoid sizes. Accordingly, the addition of anti-IL-17 neutralizing antibody suppressed this growth, suggesting that the growth effect was caused by Th17-secreted IL-17 ([Figure 4A](#fig4){ref-type="fig"}). In the absence of Th17 cells, recombinant IL-17 in the medium increased organoid growth ([Figure 4B,C](#fig4){ref-type="fig"}) and also upregulated Lgr5 and Ascl2 (stem cell marker) expression ([Figure 4D](#fig4){ref-type="fig"}).

![Th17 cells enhance colon organoid growth through IL-17.\
(**A**) Th17 cells enhance colon organoid growth in co-culture. When co-cultured with Th17 cells, colon organoids grow faster with bigger surface area. Anti-IL-17 antibody abrogates Th17 promotion of colon organoids growth. (**B and C**) Recombinant mouse IL-17 enhances mouse organoids growth as shown by representative mouse colon organoids images (**B**) and quantitative organoid area (**C**). (**D**) Western blot showing that mouse IL-17 increases the expression of colon stem cell markers, Ascl2 and Lgr5, in mouse colon organoids. (**E**) Western blot of phospho-stat3 with IL-17 (20 ng) and STAT3 inhibitor, stattic (20 μM). (**F and G**) Representative organoid images (**F**) and quantification of organoid area (**G**) with IL-17 and stattic. (**H**) Western blot of phospho-stat3 and phospho-p65 with IL-17 (20 ng) and an NF-κB inhibitor, BAY 11--7802 (5 μM). (**I and J**) Representative organoid images (**I**) and quantificaiton of organoid area (**J**) with IL-17 and BAY 11--7802. Error bars denote s.d. of triplicates. \*\*p\<0.01; \*\*\*p\<0.001. p-value was calculated based on Student's t-test. .](elife-39479-fig4){#fig4}

IL-17 activates STAT3 signaling via NF-κB {#s2-6}
-----------------------------------------

It has been reported that STAT3 activation is involved in Enterotoxigenic *E. coli-*induced colon carcinogenesis in ApcMin mice ([@bib42]). We treated mouse colon organoids with recombinant IL-17 and measured STAT3 phosphorylation by western blot. IL-17 activated STAT3, which was abrogated by the STAT3 inhibitor, Stattic ([Figure 4E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Inhibition of STAT3 by Stattic impaired colon organoid growth ([Figure 4F--G](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). IL-17 activates NF-κB in addition to STAT3 ([Figure 4H](#fig4){ref-type="fig"}). Treatment of colon organoids with an NF-κB inhibitor, BAY 11--7082, suppressed IL-17-induced STAT3 phosphorylation and organoids growth ([Figure 4H--J](#fig4){ref-type="fig"}). Hence, IL-17 seems to activate STAT3 through NF-κB, which promotes colon organoids growth.

*miR-34a* targets IL-17RD to suppress stem cell proliferation {#s2-7}
-------------------------------------------------------------

The IL-17 receptor, IL-17RA, is essential for IL-17-mediated signaling ([@bib9]). IL-17RD, an orphan IL-17 receptor, has been reported to interact with IL-17RA to mediate IL-17 signaling ([@bib45]). RT-qPCR showed that the *IL-17ra* transcript levels were similar between *C. Rodentium*-induced *miR-34a-/-* colon tumors and the wild-type colon, whereas the *IL-17rd* transcript levels were significantly increased in *miR-34a-/-* colon tumors ([Figure 5A](#fig5){ref-type="fig"}). Western blot confirmed that the IL-17RD protein level was upregulated in the *miR-34a-/- c*olon epithelial cells and tumor ([Figure 5B](#fig5){ref-type="fig"}, [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}).

![*miR-34a* targets orphan receptor IL-17RD in colon stem cells to suppresses IL-17-induced growth.\
(**A**) RT-qPCR showing relative expression of *IL-17ra* and *IL-17rd* in *C. rodentium* infected *miR-34a-/-* colonic tumors and wildtype controls. (**B**) Western blot showing increase of IL-17RD expression in *miR-34a-/-* colonic tumors. (**C**) Schematic representation of mouse *IL-17rd* 3\`UTR and the putative miR-34a binding site. (**D**) Luciferase reporter assay confirming the *miR-34a* binding sites in mouse *IL-17rd* 3\`UTR. (**E**) Immunoprecipitation showing the IL-17RA and IL-17RD complex in the colon crypt. (**F**) Western blot showing IL-17RA and IL-17RD is required for IL-17 mediated STAT3 activation. (**G and H**) *IL-17RA* and *IL-17RD* knockdown suppresses IL-17 mediated colon organoids growth as shown by representative organoids images (**G**) and quantitative organoids surface area (**H**). (**I**) IL-17RD knockdown reduces *miR-34a* deficiency-induced colon organoids growth. Error bars denote s.d. of triplicates. \*\*p\<0.01; \*\*\*p\<0.001. p-value was calculated based on Student's t-test.](elife-39479-fig5){#fig5}

RNA22 predicted a *miR-34a* binding site in the*IL-17rd* 3\`UTR ([Figure 5C](#fig5){ref-type="fig"}). The luciferase reporter assay confirmed that *miR-34a* directly targets the 3\`UTR of *IL-17rd* and suppresses IL-17RD expression ([Figure 5D](#fig5){ref-type="fig"}). Mutation of the endogenous *miR-34a* binding site in the *IL-17rd* 3\`UTR by CRISPR/CAS9 increased IL-17RD expression in wildtype mouse organoids but not in *miR-34a-/-* organoids ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Co-immunoprecipitation confirmed interaction between IL-17RA and IL-17RD in mouse colon crypts ([Figure 5E](#fig5){ref-type="fig"}). Knockdown of either *IL-17ra* or *IL-17ra* inhibited IL-17-mediated STAT3 activation (phosphorylation) and colon organoid growth ([Figure 5F--H](#fig5){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Furthermore, colon organoid growth spurred by loss of *miR-34a* was largely offset by *IL-17rd* knockdown ([Figure 5I](#fig5){ref-type="fig"}).

Consistent with its safeguard role, *miR-34a* levels were higher in Lgr5-GFP + colon stem cells than in Lgr5-GFP- cells ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). On the other hand, *miR-34b* and *miR-34c*, the other two *miR-34* family members, were barely detectable in colon epithelial cells ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). Furthermore, *miR-34a* expression levels in both CD4 +T cells and colon epithelial cells were upregulated during *C. rodentium*-induced inflammation ([Figure 5---figure supplement 2C,D](#fig5s2){ref-type="fig"}). This is consistent with the dual role *miR-34a* plays in both CD4 +T cells and colon epithelial cells.

Both epithelial and immune *miR-34a* deficiencies contribute to tumorigenesis {#s2-8}
-----------------------------------------------------------------------------

Given that *miR-34a* regulates both the immune and epithelial cells, we assessed their individual contributions to *C. rodentium*-induced colon tumorigenesis. We generated a *miR-34a* conditional knockout mice strain *Lgr5-EGFP-CreER^T2^/miR-34a^flox/flox^* by crossing *miR-34a^flox/flox^* mice with *Lgr5-EGFP-IRES-CreER^T2^* mice ([@bib15]). In this strain, intraperitoneal injection of Tamoxifen deletes *miR-34a* in Lgr5-EGFP + stem cells and their progeny ([Figure 6A](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The *miR-34a* conditional knockout did not affect IL6R and IL23R expression in CD4 +T cells, but increased CCL22 and IL17RD expression in the colon epithelium ([Figure 3---figure supplement 1E--H](#fig3s1){ref-type="fig"}). As in the uninfected *miR-34a-/-* mice, *Lgr5-EGFP-CreER^T2^/miR-34a^flox/flox^* mice did not develop colon tumors spontaneously. When infected with *C. rodentium*, 1 out of 7 mice developed colon tumors at the end of our 9 month observation period ([Figure 6B](#fig6){ref-type="fig"}). The number of CD4 +IL17+Th17 cells increased in the infected colons of *Lgr5-EGFP-CreER^T2^/miR-34a^flox/flox^* mice relative to wild-type mice ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}), but not to the degree of *miR-34a-/-* mice as shown in [Figure 2B](#fig2){ref-type="fig"}.

![Conditional *miR-34a* knockout in LGR5-EGFP + stem cells and in bone marrow transplanted immune cells contribute to tumorigenesis and Th17 cell accumulation while IL-17 neutralizing antibody blocks stem cell proliferation and tumorigenesis.\
(**A**) Schematic of the *C. rodentium*-infected *Lgr5-EGFP-CreER^T2^/miR-34a^flox/flox^* mouse model. (**B**) Frequencies of colon tumor formation in *C. rodentium* infected and uninfected *Lgr5-EGFP-CreER^T2^/miR-34a^flox/flox^* mice model. (**C**) FACS analyses of Th17 cells (CD4+/IL-17+) in *C. rodentium* infected and uninfected *Lgr5-EGFP-CreER^T2^/miR-34a^flox/flox^* mice colon. (**D**) Schematic of the *C. rodentium*-infected *miR-34a-/-* bone marrow transplant mouse model. (**E**) Frequencies of colonic tumor formation in *C. rodentium* infected and uninfected *miR-34a-/-* bone marrow transplant mice. (**F**) FACS analyses of Th17 cells (CD4+/IL-17+) in *C. rodentium* infected and uninfected *miR-34a-/-* bone marrow transplant mice colon. (**G**) Schematic of the IL-17 neutralizing antibody treatment. 500 ug isotype control or IL-17 antibody were intraperitoneally injected at the indicated days. (**H**) Immunofluorescence of Ascl2 showing IL-17 antibody largely abrogated *C. rodentium-*infection-induced colon cancer stem cell proliferation. Scale bar, 40 μm. (**I**) Western blot of Ascl2 and Lgr5 showing IL-17 antibody-abrogated *C. rodentium-*infection-induced colon stem cell marker expression. (**J**) Schematic of the IL-17 neutralizing antibody treatment. 500 μg isotype control or IL-17 antibody were intraperitoneally injected at the indicated days. (**K**) Representative H and E staining of colon tissues from IL-17 antibody or isotype control treated mice. Scale bar, 50 μm. (**L**) Frequencies of colonic tumor formation in IL-17 antibody or isotype control treated mice.](elife-39479-fig6){#fig6}

We then performed bone marrow transplantation by replacing the bone marrow in irradiated wildtype C57BL/6J mice with the bone marrow from *miR-34a-/-* mice, which resulted in mice with wildtype epithelial cells but *miR-34a-/-* immune cells ([Figure 6D](#fig6){ref-type="fig"}). The transplantation efficiency was validated to be above 90% by flow analysis ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). 6 months after *C. rodentium* infection, 3 out of the 12 mice with transplanted *miR-34a-/-* bone marrow developed colon tumors, whereas none of the wildtype mice developed tumors ([Figure 6E](#fig6){ref-type="fig"}). CD4 +IL17+Th17 cells were enriched in the infected colons of the mice with *miR-34a-/-* bone marrow transplants ([Figure 6F](#fig6){ref-type="fig"}). Caveats of this transplantation experiment include the potential confounding effects of radiation on the intestinal cells (e.g., LGR5 +cells are sensitive to radiation) and radiation-resistant cells, which can only be addressed by additional control groups with bone marrow transplantation from wild-type to wild-type and from *miR-34a-/-* to *miR-34a-/-*. Taken together, the combination of *miR-34a* deficiency in both epithelial and immune cells seems to elicit a stronger tumorigenic effect than *miR-34a* deficiency in epithelial or immune cells alone, consistent with the interaction between Th17 cells and colon epithelial cells.

IL-17 neutralizing antibody abrogates *C. rodentium*-induced colon stem cell proliferation and tumorigenesis {#s2-9}
------------------------------------------------------------------------------------------------------------

To validate the role of IL-17 in *C. rodentium*-infection-induced colon stem cell proliferation, we infected the mice with *C. rodentium* on day 0, then intraperitoneally injected the mice with IL-17 neutralizing antibody on days 1, 5, and 10, and sacrificed them on either day 15 or day 30 to harvest the colon ([Figure 6G](#fig6){ref-type="fig"}). Injection of the IL-17 antibody suppressed Ascl2 +stem cells proliferation in the infected colonic crypts according to immunofluorescence ([Figure 6H](#fig6){ref-type="fig"}) and decreased Ascl2 and Lgr5 expression according to western blot ([Figure 6I](#fig6){ref-type="fig"}).

We then intraperitoneally injected *miR-34a-/-* mice with IL-17 neutralizing antibody on day 1, 5, 10 after *C. rodentium* infection, and then every 15 days up to 2 months. 7 out of 13 *miR-34a-/-* mice developed colon tumors in the isotype control group, whereas only 1 out of 12 *miR-34a-/-* mice developed colon tumors in the antibody treated group ([Figure 6J--L](#fig6){ref-type="fig"}). Hence IL-17 antibody treatment inhibited *C. rodentium* infection induced colon tumorigenesis.

IL-17 and *miR-34a* levels are associated with human CRC {#s2-10}
--------------------------------------------------------

To investigate whether IL-17 regulates human colon epithelial growth, we grew organoid cultures from human colon tissue using an established protocol ([@bib62]) and added recombinant human IL-17 into the culture medium. Consistent with mouse organoids, addition of human IL-17 into the medium increased the sizes of human colon organoids ([Figure 7A,B](#fig7){ref-type="fig"}). RT-qPCR measurements of matched tumor and normal colon samples from 17 CRC patients ([Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}) suggested that the expression levels of the two Th17 cell markers *IL-17* and *RORC* as well as *miR-34a* target *IL-17rd* were higher in tumor tissues than that in normal colon tissues, while *miR-34a* expression levels were downregulated ([Figure 7C--F](#fig7){ref-type="fig"}).

![IL-17 and *miR-34a* expression in human CRC.\
(**A and B**) Human IL-17 enhances human colon organoids growth as shown by representative human colon organoids images (**A**) and quantitative organoids area (**B**). Error bars denote s.d. of triplicates. \*\*p\<0.01; p-value was calculated based on Student's t-test. (**C--F**) RT-qPCR of colonic tumor and normal colon tissue samples from CRC patients ([Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}) comparing *IL-17, RORC, IL-17RD*, and *miR-34a* transcript levels. Dots refer to different samples, and lines connect the paired samples. Error bars denote s.e.m. of 17 normal and cancer samples. p-values were calculated based on paired t-test.\
10.7554/eLife.39479.023Figure 7---source data 1.Source data for [Figure 7](#fig7){ref-type="fig"}.This file contains the information of CRC patients.\
10.7554/eLife.39479.024Figure 7---source data 2.Source data for [Figure 7](#fig7){ref-type="fig"}.This file contains RT-qPCR primers used in this study.](elife-39479-fig7){#fig7}

We then validated whether *miR-34a* suppresses IL-6R, IL-23R, CCL22, and IL-17RD in human cells. We ectopically expressed *miR-34a* in Jurkat cells, a human T lymphocyte cell line, and SW480 cells, a human colon epithelial cancer cell line. Western blots indicated that *miR-34a* suppressed IL-6R expression in Jurkat cells as well as CCL22 and IL-17RD expression in SW480 cells. However, *miR-34a* did not seem to suppress IL-23R expression ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

We then checked the *miR-34a* binding sequences in the 3\`UTRs of the human genes using miRanda and RNA22. Luciferase reporter assays containing the 3\`UTRs with wild-type or mutated binding sequences confirmed that *miR-34a* directly binds to these putative binding sites in *IL-17rd*, CCL22 and *IL-6r* 3\`UTRs and regulates their expression ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). On the other hand, *miR-34a* did not seem to regulate IL-23R.

Discussion {#s3}
==========

*miR-34a* is a known tumor suppressor that targets cell proliferation and apoptosis genes. In fact, RNA-seq performed on splenic CD4 +T cells and colon epithelial cells isolated from *miR-34a-/-* and wildtype mice revealed various changes in gene expression ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}), including well-known *miR-34a* target genes such as Notch1, Snai2, BCL2, and c-Met ([Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"} and [2](#fig8sdata2){ref-type="supplementary-material"}). However, *miR-34a* deficiency alone does not lead to tumorigenesis, suggesting that mere upregulation of these genes by *miR-34a* loss is not sufficient to cause cancer. Our study indicates that *miR-34a* acts as a safeguard for the inflammatory stem cell niche and reparative regeneration by modulating both the immune and epithelial responses to infection and inflammation ([Figure 8](#fig8){ref-type="fig"}). First, *miR-34a* suppresses Th17 cell differentiation and expansion by targeting IL-6R and IL-23R. Second, *miR-34a* limits Th17 cell recruitment to the epithelium by targeting CCL22. Lastly, *miR-34a* hinders IL-17-induced stem cell proliferation by targeting IL-17RD. These *miR-34a* targeting mechanisms are largely conserved between murine and human, although *miR-34a* does not seem to target IL-23R in human T cells.

![with two source data *miR-34a* regulates Th17 cell-mediated proliferation.\
A schematic illustration of the central role of *miR-34a* in Th17 cell-mediated colon stem cell proliferation. *miR-34a* suppresses Th17 cell differentiation and expansion by targeting IL-6R and IL-23R in immune cells. *miR-34a* further inhibits Th17 cells recruitment by targeting CCL22 in the colon epithelium. *miR-34a* also inhibits IL-17RD expression to suppress IL-17-IL-17RD/IL17-RA-mediated colon stem cell proliferation.\
10.7554/eLife.39479.026Figure 8---source data 1.Transcriptomic profiling of epithelial cells.\
10.7554/eLife.39479.027Figure 8---source data 2.Transcriptomic profiling of CD4+ T cells.](elife-39479-fig8){#fig8}

Colon stem cells reside at the base of the crypt, relying on the niche to provide necessary signaling cues for self-renewal. The mesenchyme beneath the niche provides many essential factors ([@bib26]). In addition, cKit+/Reg4 +colonic crypt base secretory cells interdigitate with Lgr5 +stem cells, providing the latter with Notch ligands DLL1 and DLL4, and epidermal growth factor ([@bib59]; [@bib61]). Normally, stem cells are constrained to this spatial niche and are forced to differentiate when they leave the niche. However, in human colon adenoma and carcinoma samples, Lgr5 +stem like cells are highly upregulated and are not confined to the spatial niche as in normal crypts ([@bib7]). Similarly, we have observed this enrichment and expanded distribution of stem cells in *C. rodentium-*induced colon tumors in *miR-34a-/-* mice. Inflammatory cytokines such as IL-17 potentially provide an enlarged 'inflammatory niche' by stimulating receptors such as IL-17RD on the stem cells, enabling them to ignore the constraints of the crypt base and proliferate away from the crypt base mesenchyme and secretory cells. Interestingly, IL-17RD amplifies IL-17RA signaling in a way analogous to Lgr5 receptor amplification of Wnt signaling for self-renewal.

Non-coding RNAs occupy the majority of the mammalian genome ([@bib44]; [@bib50]). Evolutionarily, the percentage of genome devoted to the non-coding region is consistently associated with the complexity of the organism, rising from less than 25% in prokaryotes, 25--50% in simple eukaryotes, more than 50% in fungi, plants and animals, to approximately 98.5% in humans---which have a genome size that is three orders of magnitude larger than prokaryotes ([@bib49]). Compared to microRNA, the role of long non-coding RNA (lncRNA) in regulating tumors has just started to be appreciated ([@bib35]; [@bib57]; [@bib66]). In fact, lncRNA has been shown to regulate *miR-34a* in human CRC, especially in cancer stem cells ([@bib80]). Similar to *miR-34a*, many of the lncRNAs with strong functions in tumors are largely dispensable for normal development and tissue homeostasis ([@bib83]; [@bib52]). It is possible that the abundance of non-coding RNAs in mammals may provide extra surveillance to protect tissue integrity during stress conditions such as inflammation, which are often not captured by laboratory animal models raised in well-controlled circumstances.

The *miR-34a* mimic was the first microRNA mimic to reach clinical trial for cancer therapy ([@bib13]; [@bib6]). Previous studies largely focused on the role of *miR-34a* to induce cell cycle arrest, senescence, and apoptosis. This study suggests that enhancing *miR-34a* levels may have additional benefits of suppressing Th17 cells and IL-17 stimulation of cancer stem cells in the tumor microenvironment. Furthermore, inflammatory cytokines such as IL-6 can suppress *miR-34a* to increase epithelial-mesenchymal transition (EMT) ([@bib58]), so boosting *miR-34a* may mitigate inflammation-induced CRC invasion and migration. It might be worth paying extra attention to CRC with Th17 cell enrichment and evaluating therapeutics effects based on CRC classification, especially on the inflammatory and stem cell-like subtypes ([@bib60]).

Materials and methods {#s4}
=====================

Transgenic mice and bacterial infection {#s4-1}
---------------------------------------

C57BL/6J and *B6(Cg)-Mir34atm1Lhe/J* mice ([@bib21]) were ordered from the Jackson Laboratory. *Lgr5-EGFP-creER^T2^/miR-34a^flox/flox^* mice were generated as described as previously ([@bib15]). Cre recombinase was induced by intraperitoneal injection of tamoxifen (Sigma) dissolved in sterile corn oil at a dose of 75 mg/kg before infection with *C. rodentium*. Mouse maintenance and procedures were approved by Duke University DLAR and followed the protocol (A286-15-10). *C. rodentium* strain DBS100 was purchased from ATCC and cultured according to previously described methods ([@bib68]). 2 × 10^9^ C.F.U *C. rodentium* were infected into 8 weeks old mice by oral gavage.

Bone marrow transplantation {#s4-2}
---------------------------

The bone marrow transplantation procedures were performed as previously described ([@bib3]). Male C57BL/6J.SJL mice (Ly5.1) with the *Ptprc*^b^ leukocyte marker CD45.1/Ly5.1 obtained from the Jackson Laboratory were used as recipients for transplantation at the age of 8--10 weeks. The recipient mice received 1000 Rad (1Gy, filter 4) whole body lethal irradiation on XRad320. After 6 hr, the irradiated mice received bone marrow cells from male C57BL/6J miR34a -/- donor mice with *Ptprc*^b^ leukocyte marker CD45.2/Ly5.2. The donor femurs were collected aseptically, and the bone marrow canals were washed out with sterile media. 6 million cells per mouse were transplanted into lethally irradiated recipients via tail vein injection. Mice were housed and received sulfamethoxazole trimethoprim medicated, acidified water for 4 weeks. 6 weeks after reconstitution, blood was collected from the recipient mice, and the reconstituted blood cell lineages were analyzed by flow cytometry using CD45.1-PE (Biolegend) and CD45.2-FITC (Biolegend).

Clinical specimen and colon organoid culture {#s4-3}
--------------------------------------------

Frozen CRC specimens and paired controls were acquired from Weill Cornell Medical College (WCMC) Colon Cancer Biobank for evaluation of Th17 cell-related gene expression. Surgically resected fresh normal human colon tissues were obtained from Duke University hospital. The study was approved by the ethical committee of Duke University hospital, Duke University, and WCMC. All samples were obtained with informed consent.

Mouse and human colon crypt isolation and organoid culturing were performed as described previously ([@bib62]). To investigate CCL22 regulation on Th17 cell migration and IL-17RA and IL-17RD regulation on organoids growth, lentiviral vector carrying shRNA against *CCL22*, *IL-17ra* or *IL-17rd* were purchased from Sigma and infected into organoids according to previously described protocols ([@bib41]).

CD4 +T cell isolation and Th17 cell differentiation {#s4-4}
---------------------------------------------------

To investigate Th17 cell enrichment in *C. rodentium-*infected colons, CD4 +T cells were first isolated from mouse colon as described previously ([@bib81]). Briefly, after washing with cold PBS, the mouse colon was cut into 0.5--1 cm pieces and incubated in Ca^2+^ and Mg^2+^ free PBS containing 0.37 mg/ml EDTA and 0.145 mg/ml DTT in a shaking incubator at 37°C for 15 min. The supernatant was decanted, and the remaining tissue was further incubated in RPMI-1640 containing 5% fetal calf serum, 20 mM HEPES, 100 U/ml each of penicillin and streptomycin, and 0.1 mg/ml collagenase dispase (Sigma) while shaking at 37°C for 90 min. After filtering through 70 µm cell strainers, the cells were collected by centrifugation, and the pellet was suspended in 35% percoll solution (Sigma). The cells were then collected by centrifugation at 2000 rpm for 20 min. CD4 +T cells were isolated using a mouse CD4 +T cell isolation kit (StemCell Technology). Then 10,000 CD4 +T cells were counted for flow cytometry. After staining for CD4 and IL-17, Th17 cells were analyzed by flow cytometry.

To evaluate the effect of IL-23R on Th17 cell differentiation, CD4 +T cells were isolated from mouse spleen as described previously ([@bib81]). Briefly, the spleen was minced and squeezed through 70 µm cell strainers to obtain single cells. After collection by centrifugation, the cells were suspended into 35% percoll solution (Sigma) with heparin, followed by incubation in red cell lysis buffer (Abcam) to get rid of red blood cells. The cells were then washed, and CD4 +T cells were isolated using a mouse CD4 +T cell isolation kit (StemCell Technology). Isolated CD4 +T cells were cultured in 24-well plate coated with anti-CD3e and anti-CD28 antibodies in 1640 RPMI medium with 10% FCS and recombinant mouse IL-2 (rmIL2, 20 ng/mL) at 1 × 10^6^/ mL according to the previous protocol ([@bib85]). Lentiviral vectors carrying shRNA against *IL-23r* were purchased from Sigma and infected into CD4 +T cells following previously described protocols ([@bib8]). After selection by antibiotics, the cells were induced to differentiate into Th17 cells using the FlowCellect Mouse Th17 Differentiation Kit according to the protocol (EMD Millipore). Th17 cell differentiation efficiency was measured by flow cytometry by CD4 and IL-17 staining.

Co-culture Th17 cells with organoids {#s4-5}
------------------------------------

After differentiation from CD4 +T cells, Th17 cells were co-cultured with colonic crypts at a 10:1 ratio in Matrigel. To activate and maintain Th17 cells, rmIL-2 (20 ng/ml; Pepro-tech), mIL-6 (50 ng/ml; Pepro-tech), TGF-β (10 ng/ml; Pepro-tech), mIL-23 (30 ng/ml; Pepro-tech) were added into the ENR organoids culture medium. A neutralizing monoclonal antibody against IL-17(Abcam) was used to abrogate IL-17 specific effects of Th17 cells.

Histochemical staining {#s4-6}
----------------------

Selected colon tissues from wildtype and *miR-34a-/-* mice euthanized at 2 days, 2, 4, and 6 months after *C. rodentium* infection were fixed in 10% neutral buffered formalin, processed routinely and embedded in paraffin, sectioned at five microns, and stained with hematoxylin and eosin. Glass slides were scanned via high resolution virtual slide imaging at 40x (Aperio, Leica Biosystems) and then reviewed by a board-certified veterinary pathologist with experience in mouse tumor biology (JE) without knowledge of genotype. Lesions were scored according to established murine pathology ([@bib10]). Representative proliferative colonic lesions were selected for recuts and β-catenin immunohistochemistry (IHC) was performed. IHC was conducted with a rabbit monoclonal antibody against β-catenin (1:400, Abcam) after epitope retrieval. The secondary detection system was a labelled polymer-HRP anti-rabbit (Dako).

Chemotaxis assays {#s4-7}
-----------------

The chemotaxis assay was performed as described previously ([@bib34]). Briefly, 1 × 10^5^ Th17 cells were applied to the upper well of the ChemoTex chambers (96-well, 5 μm pore size; NeuroProbe). Conditional medium from *miR-34a-/-* colon organoids or control organoids was added in the lower chamber. To evaluate the effect of CCL22 on Th17 migration, a neutralizing monoclonal antibody against CCL22 (R and D) was included in the conditional medium. After a 2 hr incubation, the cells in the upper wells were removed, and the migrated cells were collected by centrifugation. Migrated cells were counted using a hemocytometer.

Immunofluorescence {#s4-8}
------------------

Immunofluorescence was performed on paraffin-embedded colon sections. After rehydration and antigen retrieval, the sections were blocked by 2% horse serum in PBS for 2 hr at RT and incubated with anti-Ascl2 (1:200, Santa Cruz), anti-IL17 (1:200, Abcam), anti-CD4 (1:50, R and D Systems) or anti-GFP (1:500, Abcam) primary antibodies in antibody diluent buffer (DAKO) overnight at 4°C. After washing, the sections were then incubated with Rhodamine Red or Alexa fluor 488 labeled secondary antibodies (Invitrogen) for 1 hr at room temperature. After counterstaining with DAPI (Invitrogen), the slides were observed on an Axio Imager upright microscope (Zeiss).

Flow cytometry analysis {#s4-9}
-----------------------

Th17 cells were analyzed by CD4 and IL-17 staining. Briefly, single cells were fixed with 4% formaldehyde and further permeabilized by methanol. The cells were then incubated with anti-IL-17 (1:200, Abcam) and anti-CD4 (1:100, R and D Systems) antibodies, followed by incubation with APC or FITC labeled secondary antibody (Invitrogen). The samples were analyzed using a Beckman Coulter flow cytometer. The raw FACS data were analyzed with the FlowJo software.

Quantitative real-time PCR {#s4-10}
--------------------------

Total RNA was extracted from the tissue using the RNeasy mini kit (Qiagen). cDNA was synthesized from 500 ng of total RNA in 20 µl of reaction volume using the High Capacity cDNA Archive Kit (Applied Biosystems). Quantitative PCR was carried out using TaqMan assays (Applied Biosystems) to detect *miR-34a* and hIL-17, and the SYBR Green System (Applied Biosystems) for all other gene expression measurements. *miR-34a* primers were purchased from Applied Biosystems, and hIL-17 primers were purchased from Thermo Fisher. Other qPCR primers were synthesized by IDT, and the sequences are listed in [Figure 7---source data 2](#fig7sdata2){ref-type="supplementary-material"}. All relative gene expression measurements utilized at least three biological replicates for both the wild-type and miR34a deficient experimental groups with three technical replicates per biological replicate. The expression of each gene was defined using the threshold cycle (Ct), and the relative expression levels were calculated using the 2-△△Ct method after normalization to the ß-actin expression level.

Western blot {#s4-11}
------------

Whole cell lysate was prepared in a RIPA lysis buffer (Millipore) with protein inhibitor (Roche). Proteins were first separated by 10% SDS-PAGE and then transferred to a Hybond membrane (Amersham). The membranes were incubated with primary antibodies for anti-lgr5 (1:500, Santa Cruz), anti-ASCL2 (1:1000, Bioss), anti-IL23R (1:500, R and D Systems), anti-CCL22(1:500, R and D Systems), anti-IL17RD (1:500, R and D Systems), anti-IL17RA (1:500, R and D Systems), anti-pSTAT3 (1:1000, Cell Signaling) or anti-actin (1:2000, Cell Signaling) in 5% milk/TBST buffer (25 mM Tris pH 7.4, 150 mM NaCl, 2.5 mM KCl, 0.1% Triton-X100) overnight and then probed for 2 hr with secondary horseradish peroxidase (HRP)-conjugated anti-goat or anti-rabbit IgG (Santa Cruz). After an extensive wash with PBST, the target proteins were detected on membrane by enhanced chemiluminescence (Pierce).

Sequence mutation and gene knockdown gRNA:CAGAATGATGGCGGTGGCAG-TGG was designed for mutation of sequence complementary to *miR-34a* binding site in the mouse *IL-17rd* 3UTR. The gRNA was then vector pLentiCRISPR v2. and transfected into mouse single colon stem cells. DNA sequencing of single colonies confirmed successful deletion of *miR-34a* binding in mouse *IL-17rd* 3UTR. Mutagenesis for luciferase reporter assay was performed using QuickChange Site-Directed Mutagenesis Kit (Stratagene). shRNAs for knockdown of *IL-6R, IL-23R, IL-17RA, IL-17RD* and *CCL22* were purchased from Sigma. PCR were performed using primers to amply three most APC mutation regions in mouse colon cancer. Primers: 'GCCATCCCTTCACGTTAG' and 'TTCCACTTTGGCATAAGGC' for DNA sequence contains mutation 1; Primers: 'TGACAGCACAGAATCCAGTG' and 'TACCAAGCATTGAGAG' for DNA sequence contains mutation 2 (B); Primers: 'TAGGCACTGGACATAAGGGC' and 'GTAACTGTCAAGAATCAATGG' for DNA sequence contains mutation 3.

Statistical analysis {#s4-12}
--------------------

Data were expressed as mean ± standard deviation (s.d.) of three biological replicates. Student T-tests were used for comparisons, with p\<0.05 considered significant. Patient data were expressed as mean ± standard error of the mean (s.e.m.). Paired T-tests were used for comparison of the 17 matched patient normal colon and CRC samples.
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\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for choosing to send your work, \"miR-34a is a microRNA safeguard for the inflammatory colon stem cell niche\", for consideration at *eLife*. Your initial submission has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. Although the work is of interest, we regret to inform you that the findings at this stage are too preliminary for further consideration at *eLife*.

Specifically, each of the three reviewers raised a number of major points. Reviewers 1 and 3 raise the need to provide histological and pathology analyses to better characterize the relation to tumor susceptibility. All reviewers commented that you haven\'t adequately shown that mi34 null mice are enriched for stem cells. This necessitates either FACS quantification of purified ISCs. Reviewer 1 raises a discrepancy in Figure 2 data that needs resolving. Reviewers 1 and 3 raised the need to know the relative expression levels of miR-34a and how they change. Reviewers 2 and 3 raise issues relating to your links to inflammation. Reviewer 3 indicates the need for CRISPR/CAS to complement the overexpression data, and this seems feasible in organoids and important to illuminate the specificity of your phenotype. Finally, reviewer 3 raises an important concern related to better controls needed to establish Tamoxifen efficiency. This reviewer also raises a key issue relating to conservation of the 3\'UTR sites, and conversely, reviewer 1 raises an issue relating to the specificity to miR34a versus other family members. Addressing these issues would take considerable work, significantly more than the 2 months expected for revised manuscripts. However, the reviewers think the work is interesting, in principle, so a revised manuscript addressing these issues would be considered. Such a revised manuscript would be technically a \"new\" submission that undergoes the usual 2-step review, but the first step would be conducted by the reviewing editor and (usually) reviewers.

Reviewer \#1:

Wang et al. reported that miR-34a functions in the colon to govern homeostasis and antagonize transformation upon bacteria infection. This occurs via both cell autonomous and non-autonomous mechanisms. Overall, if substantiated, the findings could be of broad appeal to the *eLife* readership. However, several important issues need to be addressed.

Figure 1: miR-34a-/- renders infected mice susceptible to colon tumorigenesis. The authors need to substantiate their conclusions with pathological and histological analysis to show the tumor stage and progression.

Figure 1: The increase of LGR5 and ASCL2 shown by Western: is this based on purified ISCs, or is it reflecting an increase from total colon tissue (reflective of increased cell number expressing LGR5 and ASCL2)?

Figure 2: It appears that miR-34a-/- alone does not significantly increase IL17 (Figure 2A-B). However from immunostaining (Figure 2C-D), miR-34a-/- uninfected colon clearly has increased IL17+ cells, whereas WT uninfected colon seems non-phenotypic. This discrepancy needs to be explained experimentally.

Figure 4: It appears that there is basal pSTAT3 activity in normal uninfected colon epithelium, and Stattic suppresses organoid formation/survival independent of IL-17. Is it true that Stattic treatment alone will give rise to a phenotype similar to IL-17+ Stattic? If so, it is difficult for a reviewer to accept a conclusion that pSTAT3 is the mediator of proliferation upon IL-17 stimulation.

Figure 8: Is miR-34a expression specific to the stem cells? What about the other miR-34 family members that might function analogously? What are the global gene expression changes in either epithelial or immune cells upon miR-34a acute deletion? What are miR-34a\'s direct targets besides the cherry-picked ones reported here? The authors need to address these issues.

Reviewer \#2:

In their article \"*mir-34a* is a microRNA safeguard for inflammatory colon stem cell niche\" Shen and colleagues examine the role of mir-34a in limiting inflammatory pathology and tumorigenesis in following Citrobacter infection. In doing so they uncover a number of mir-34a targets in both immune and epithelial cells that synergize to promote pathology. I believe this is an intriguing study and is clinical relevant for a number of intestinal inflammatory conditions. However I have a few concerns regarding controls and interpretations of experiments that should be addressed prior to consideration for publication in *eLife*.

• The authors claim that the crypts of infected mir34ko animals were enriched for stem cells based on increased Lgr5 and Ascl2 expression. Without lineage tracing stem cell it is difficult to make this claim as differentiated cells could merely be up-regulating the expression of these stem cell markers. The title of this manuscript may also need to be modified to reflect this.

• The authors claim that the 3\' UTR of IL23R has a mir34a-binding site, in the absence of which there is more IL-17A production from CD4 T cells that contributes to pathology. What are the absolute numbers of these pathological Th17 cells? It is difficult to claim there are more Th17 cells based on frequencies on a FACS plot. Were they acquired from the gut or draining lymph node? Other cell types also express IL23R, for example ILCs. What is their level of IL-17A expression? Further what is the level of IL23R expression in the mir34aKo animals?

• The authors test a role for stat3 in their model and claim that IL-17A activates stat3. Since IL17R\'s are known to signal through NF-κB, are these receptors also activating stat3 or is this a secondary effect of a downstream cytokine (for example IL-6 or IL-24) being produced?

• What is the level of epithelial IL17RD expression in mir34aKO animals?

• Does treatment of infected mir-34a KO with anti-IL17A abrogate pathology and tumorigenesis?

Reviewer \#3:

In this manuscript, Wang et al. propose a novel function for miR-34a, a member of a family of p53-regulated miRNAs, in controlling the inflammatory response of the colon to infection by *Citrobacterium rodentium*.

They present a model in which miR-34a directly represses IL23R and CCL22 in CD4^+^ cells and IL17RD in the intestinal cells. Repression of these targets by miR-34a is necessary to prevent excessive Th17 differentiation and migration, and to blunt the proliferative response of the intestinal stem cells to IL17. By doing so, miR-34a acts as a barrier against inflammation-induced intestinal tumorigenesis. These findings are of substantial relevance and broad interest to the readership of *eLife*.

The manuscript is clearly written, the experiments are well described, and their results are largely consistent with the model proposed by the authors. Major strengths include the use of genetically engineered mice harboring targeted deletion of miR-34a and the use of intestinal organoids derived from these mice to explore the mechanisms through which miR-34a affects intestinal tumorigenesis and inflammation.

Despite these major strengths, the manuscript has a few weaknesses that in my opinion need to be addressed. More specifically:

1\) One of the central claims of the authors is that loss of miR-34a leads to high incidence of colon cancers in *Citrobacterium*-infected mice. This claim is not adequately supported by the evidence presented in the manuscript. The only analysis provided in addition to the statement that 11 out of 20 mice developed tumors, are a single H&E staining (Figure 1A) and a single macroscopic image of a dissected colon (Figure 1B). Given the importance of this claim much more details should be provided. In particular, the authors should include a detailed histopathologic characterization of the lesions by an experience animal pathologist. This should be corroborated by low and high magnification images, immunostaining for β catenin, and histologic grading. Additional key questions that should be addressed include: Are the tumors invasive/metastatic? Are they adenocarcinomas or adenomas? Are they APC mutant? The pro-tumorigenic effect of miR-34 loss in this context is a major novelty of the manuscript, and therefore I believe these are important details that need to be included to support and better define the claim.

2\) A more detailed characterization of the dynamic of inflammation in response to *Citrobacterium* infection in miR-34a wt and mutant mice should be provided. The authors only show the consequences at 11 days and at 6 months (Figure 1A), but it would be important to know what the intestine looks at intermediate time points. Does a state of chronic inflammation and intestinal stem cell hyper-proliferation develop in the miR-34a-null mice that would explain the increased tumor incidence at later time points?

3\) Another essential aspect that needs to be addressed concerns the expression dynamic of miR-34a in the intestinal epithelium and in CD4^+^ cells undergoing Th17 differentiation. Knowing the relative expression levels of miR-34a, and how they change in response to *Citrobacterium* infection is essential to assess the plausibility of the proposed mechanism.

4\) The authors propose that miR-34a directly targets IL17RD, IL23R, and CCL22 by binding to their respective 3\'UTRs. In support of this hypothesis they present data that luciferase reporters containing the wt or mutant 3\'UTR are differentially sensitive to miR-34a overexpression. While this is a reasonable idea, it is important to recognize that in these experiments the ectopically expressed miRNA achieves levels that are often hundred folds greater than their physiologic levels. A more conclusive and elegant experiment would be to use CRISPR-Cas9 to introduce a point mutation in the predicted binding site and show that this leads to upregulation of the gene product in mIR-34a wt, but not in miR-34a-null cells. This experiment should be relatively straightforward to perform to validate the IL17RD site in intestinal organoids derived from miR-34a wild type and mutant mice.

5\) An additional reason I am not fully convinced that miR-34a targets these genes directly via the proposed sites is that none of the three 3\'UTR sites is conserved in the human genome. The authors unfortunately fail to discuss this important point in the manuscript, a point that is even more relevant since they suggest that miR-34a plays a similar mechanism in suppressing colon cancer formation in humans (Figure 7).

6\) Finally, the experiments described in Figure 6 using conditional deletion of miR-34a in the intestine with Lgr5-Cre-ER are elegant but difficult to interpret because the authors do not show how efficiently tamoxifen delivery lead to bi-allelic miR-34a deletion in the intestinal epithelium. Poor Cre-mediated recombination could be a simple explanation for the reduced tumor incidence. This should be addressed if the authors want to include this experiment in the manuscript.

Another useful control would be to include a cohort of mice generated by transplanting the bone marrow from miR-34a-/- mice into tamoxifen-treated Lgr5-Cre-ER;miR-34a fl/fl recipients. If the model proposed by the authors is correct, these animals should display a tumor incidence in response to *Citrobacterium* infection analogous to what was observed in miR-34a-/- animals. I understand, however, that performing these experiments would be a major undertaking in terms of time and resources and I would not insist on having this latter experiment included in the revised paper.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for submitting your article \"*miR-34a* is a microRNA safeguard for inflammatory colon oncogenesis\" for consideration by *eLife*. Your article has been reviewed by 3 peer reviewers, including Elaine Fuchs as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen Kevin Struhl as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Andrea Ventura (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers overall found your manuscript to be substantially improved and in principle of interest to *eLife* readership. However, there are still several concerns, which in our view are significantly substantial that we feel will need addressing experimentally. Normally, we do not pursue with the process if we feel that it could take the authors more than 2 months to complete. However, given the enthusiasm for your paper, we are willing to leave this door open for you, and encourage you to address the issues below, add the experiments, revise the text and figures and resubmit. If you address these final issues, I can ensure a rapid turnaround, but please do not take our enthusiasm for your work as an acceptance of your manuscript. The issues below need to be dealt with in a satisfactory way.

The main lingering issue centers on the quality of some of your data and the lack of appropriate controls, which call into question your interpretation. Specifically, you claim that the crypts of infected mir34ko animals are enriched for stem cells based on increased Lgr5 and Ascl2 expression. Without either lineage tracing the stem cells or some kind of functional assay, this claim is not substantiated. Differentiated cells could merely be up-regulating the expression of these stem cell markers. The title of your paper is not justified without these data.

An additional concern raised by reviewer 2 is that you claim that the 3\' UTR of IL23R and IL16R has a mir34a-binding site, in the absence of which there is more IL17 production from CD4 T cells that contributes to pathology. What are the absolute numbers of these pathological Th17 cells? It is difficult to claim there are more Th17 cells based on frequencies on a FACS plot. Were they acquired from the gut or draining lymph node? Other cell types also express IL23R, for example ILCs. What is their level of IL-17A expression? Further what is the level of IL23R expression in the mir34aKo animals?

Of additional concern, your team has tested for a role for stat3 and claim that IL17A activates stat3. Since IL17R\'s are known to signal through NF-κB, are these receptors also activating stat3 or is this a secondary effect of a downstream cytokine (for example IL-19/20/ IL-24) being produced? Again, it is difficult to make this link without the underlying mechanisms or at least a possible discussion of one. Related to this, what is the level of epithelial IL17RD expression in mir34aKO animals? Does treatment of infected mir-34a KO with anti-IL17A abrogate pathology and tumorigenesis?

In your Lgr5-GFP-CreER; mIR34a fl/fl mouse model, how are the mRNA or protein levels of proposed mIR34a downstream targets affected? CCL22, IL17 etc. (Figure 6A). Figure 6D is lacking the ko\>ko and WT\>WT BM chimera control. It is difficult to interpret the use of WT controls, which have not undergone irradiation (a treatment known to affect the intestinal compartment).

Finally, reviewer 3 points out that the volcano plots shown in the supplementary figure should be complemented by including cumulative distribution (cdf) plots with logFC on the x axis comparing predicted miR34a targets to the rest of the transcriptome. These plots should show preferential derepression of the miR-34a targets (i.e. a shift to the right of the cdf plot compared to background). These are standard plots in the miRNA field and the reason for asking to include them has to do with the initial concerns raised regarding the absolute levels of miR-34a in these tissues. Demonstrating a signal attributable to miR-34a loss in the cdf plots would be conclusive evidence that the levels of miR-34a in these tissues are high enough to cause substantial target repression.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"*miR-34a* is a microRNA safeguard for *Citrobacter*-induced inflammatory colon oncogenesis\" for further consideration at *eLife*. Your revised article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Kevin Struhl as the Senior Editor.

The manuscript has been improved but there is still one issue that can be addressed textually before acceptance, as outlined below:

Reviewer 2 makes a valid point, namely that in Figure 2---figure supplement 1 you claim to evaluate ILC3 based on CD117+ CD45+ cells. As this is not a specific straining strategy for ILC3, you should revise your claim that ILC3s are not affected in your system. Once this is addressed textually, there should be no further need for adjustments.

The set of reviews are listed below:

Reviewer \#1:

The reviewers have addressed our concerns satisfactorily, and in our view, the manuscript is now suitable for publication in *eLife*.

Reviewer \#2:

The revised manuscript is significantly improved. The newly included experiments have validated many of the author\'s initial claims and changes to the text have corrected over statements. I believe the study is well suited for publication in e*Life*.

I have one comment that can be addressed textually.

In Figure 2---figure supplement 1 the authors claim to evaluate ILC3 based on CD117+ CD45+ cells. This is in no way a specific straining strategy for ILC3 and the authors should revise their claims of ILC3s not being effected in their system based on this rather rudimentary analysis.

Reviewer \#3:

I am satisfied with the changes made by the authors, who have addressed my remaining concerns.

10.7554/eLife.39479.033

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> Wang et al. reported that miR-34a functions in the colon to govern homeostasis and antagonize transformation upon bacteria infection. This occurs via both cell autonomous and non-autonomous mechanisms. Overall, if substantiated, the findings could be of broad appeal to the eLife readership. However, several important issues need to be addressed.
>
> Figure 1: miR-34a-/- renders infected mice susceptible to colon tumorigenesis. The authors need to substantiate their conclusions with pathological and histological analysis to show the tumor stage and progression.

We agree with reviewer that pathological and histological analysis is needed to substantiate our conclusion. Dr. Jeffrey Everitt, a board-certified veterinary pathologist with extensive murine tumor experience, reviewed whole slide scanning of H&E stained colon sections from day 11, month 2, 4, and 6 post infection. His review confirmed that colon tumorigenesis and progression in the infected miR-34a -/- KO mice was histologically similar to those noted in other murine colon carcinogenesis models \[1\] (Figure 1A and Figure 1---figure supplement 1A).

In detail, histopathological changes of pre-neoplasia and neoplasia were limited to the miR-34a /- genotype and were first noted at the four-month time point. Microscopic sections from wild type control mice were free of dysplastic and neoplastic changes at four-month (0/2) and six-month time points (0/20) following infection. In miR34a-/- mice no dysplasia or early neoplasia was present at a two-month time point (0/4), whereas at four months half the animals (2/4) had dysplastic change microscopically. At the six-month time point (11/20) miR-34a-/- mice had microscopic changes ranging from dysplasia (2/20), to adenoma (7/20), to adenocarcinoma (2/20). The tumors were considered well-differentiated. Interestingly, the animal with a colonic adenocarcinoma in the distal colon also had a squamous cell carcinoma of the rectum.

We also checked the livers and lungs of the infected miR-34a-/- mice, and found no metastases (Figure 1---figure supplement 1B, C).

> Figure 1: The increase of LGR5 and ASCL2 shown by Western: is this based on purified ISCs, or is it reflecting an increase from total colon tissue (reflective of increased cell number expressing LGR5 and ASCL2)?

Western blots were performed on the total colon tissue.

> Figure 2: It appears that miR-34a-/- alone does not significantly increase IL17 (Figure 2A-B). However from immunostaining (Figure 2C-D), miR-34a-/- uninfected colon clearly has increased IL17+ cells, whereas WT uninfected colon seems non-phenotypic. This discrepancy needs to be explained experimentally.

In Figure 2C-D, we only examined infected colon from WT and miR-34a-/- mice (marked WT infected and miR-34a-/- infected). Figure 2C showed CD4 staining and Figure 2D showed IL-17 staining of infected colon tissue, not uninfected colon.

> Figure 4: It appears that there is basal pSTAT3 activity in normal uninfected colon epithelium, and Stattic suppresses organoid formation/survival independent of IL-17. Is it true that Stattic treatment alone will give rise to a phenotype similar to IL-17+ Stattic? If so, it is difficult for a reviewer to accept a conclusion that pSTAT3 is the mediator of proliferation upon IL-17 stimulation.

We treated the colon organoids with 20μM Stattic along with different amounts of IL-17A (2ng, 4ng and 8ng). Stattic alone significantly suppressed colon organoids growth and pSTAT3 activity. 2ng IL-17A mitigated the effect of Stattic, 4ng IL-17A rescued colon organoids growth and pSTAT3 activity, and 8ng IL-17A further enhanced colon organoids growth and pSTAT3 activity (Figure 4---figure supplement 7).

The original manuscript only included the treatment condition of 20μM Stattic and 2ng IL-17A (Figure 4E-G). In the revised manuscript, we have clarified this condition in the Figure 4 legend and included all conditions in Figure 4---figure supplement 7 to provide readers with the complete picture.

> Figure 8: Is miR-34a expression specific to the stem cells? What about the other miR-34 family members that might function analogously? What are the global gene expression changes in either epithelial or immune cells upon miR-34a acute deletion? What are miR-34a\'s direct targets besides the cherry-picked ones reported here? The authors need to address these issues.

We isolated Lgr5-GFP+ and Lgr5-GFP- cells by FACS and measured their respective miR-34a levels by RT-qPCR. miR-34a expression is three-fold higher in Lgr5-GFP+ stem cells than in Lgr5-GFP- cells (Figure 5---figure supplement 9A).

We also measured the levels of miR-34b and miR-34c, the other two members in the miR-34a family, in colon epithelial cells by RT-qPCR. miR-34b and miR-34c expression levels were barely detectable, about one hundred fold lower than miR-34a (Figure 5---figure supplement 9B).

We performed RNA-seq on splenic CD4^+^ T cells and colon epithelial cells isolated from miR34a-/- and wildtype mice, which revealed global gene expression changes (Figure 8---figure supplement 13 and Figure 8---source data 1 and 2). It is worth noting that RNA-seq tends to pick up more abundantly expressed genes depending on the sequencing depth. The known direct miR34a target genes such as Notch1, Snail2, BCL2, and c-Met were upregulated in miR-34a-/- cells. They could have certainly contributed to tumorigenesis as previously reported. However, because the uninfected miR-34a-/- mice did not form spontaneous tumors, these genes alone were not sufficient to cause tumorigenesis without the immune system. We have added the following sentence to the Discussion section of the manuscript:

"miR-34a is a known tumor suppressor that targets cell proliferation and apoptosis genes. In fact, RNA-seq performed on splenic CD4^+^ T cells and colon epithelial cells isolated from miR-34a-/- and wildtype mice revealed various changes in gene expression (Figure 8---figure supplement 13), including well-known miR-34a target genes such as Notch1, Snail, BCL2, and c-Met (Figure 8---source data 1 and 2). However, miR-34a deficiency alone does not lead to tumorigenesis, suggesting that mere upregulation of these genes by miR-34a loss is not sufficient to cause cancer."

Interestingly, IL-6R was also shown upregulated in CD4^+^ T cells. The IL-6/IL-6R axis plays an important role in Th17 cell differentiation. IL-6R has previously been reported to be a miR-34a target in epithelial cells \[2\] but whether the miR-34a-IL-6R axis plays any role in immune cells has not been reported. We validated that miR-34a directly targets IL6R in CD4^+^ T cells, which suggests that miR-34a targets both IL-6R and IL-23R to modulate Th17 cell differentiation (Figure 3). This finding that miR-34a targets both steps (IL-6R and IL-23R) in Th17 differentiation strengthens our conclusion that miR-34a is an important regulator for the inflammatory niche, and has been added to the revised manuscript.

> Reviewer \#2:
>
> In their article \"mir-34a is a microRNA safeguard for inflammatory colon stem cell niche\" Shen and colleagues examine the role of mir-34a in limiting inflammatory pathology and tumorigenesis in following Citrobacter infection. In doing so they uncover a number of mir-34a targets in both immune and epithelial cells that synergize to promote pathology. I believe this is an intriguing study and is clinical relevant for a number of intestinal inflammatory conditions. However I have a few concerns regarding controls and interpretations of experiments that should be addressed prior to consideration for publication in eLife.
>
> • The authors claim that the crypts of infected mir34ko animals were enriched for stem cells based on increased Lgr5 and Ascl2 expression. Without lineage tracing stem cell it is difficult to make this claim as differentiated cells could merely be up-regulating the expression of these stem cell markers. The title of this manuscript may also need to be modified to reflect this.

We thank reviewer for the rigor. We have modified the title to: *miR-34a* is a microRNA safeguard for inflammatory colon oncogenesis.

> • The authors claim that the 3\' UTR of IL23R has a mir34a-binding site, in the absence of which there is more IL-17A production from CD4 T cells that contributes to pathology. What are the absolute numbers of these pathological Th17 cells? It is difficult to claim there are more Th17 cells based on frequencies on a FACS plot. Were they acquired from the gut or draining lymph node? Other cell types also express IL23R, for example ILCs. What is their level of IL-17A expression? Further what is the level of IL23R expression in the mir34aKo animals?

After CD4 T cell isolation, we counted 10,000 CD4^+^ T cells for each FACS analysis. According to the percentage of the interested cell population of FACS analysis, 710 out of 10,000 were IL17+ cells in the infected wildtype colon tissue while 2410 out of 10,000 were IL-17+ cells in the infected miR-34a-/- colon tissue, as indicated by the percentages on the FACS plots (Figure 2B). We have clarified the total CD4^+^ T cell numbers in the figure legend and the methods under the section title "CD4^+^ T cell isolation and Th17 cell differentiation".

The CD4^+^ cells were acquired from the gut. We have clarified this in the main text and figure legend.

The protocol we found for isolating ILCs requires lineage markers (CD3, CD5, CD19, Ly6 C/G), surface staining makers (IL7α, CD45, CCR6) and transcription factors (RORγ, GATA3). The sorting results was limited by our flow cytometry ability. We attempted twice without convincing results. Furthermore, to characterize IL23R and IL-17A levels in ILCs at different post-infection points will require repeating of the *Citrobacter* infection experiments and will take more than 8 months (6 months for the tumors to form). Therefore, we were not able to complete this experiment. We have added this caveat that ILCs also express IL23R and may play a role in the observed phenotype to our Discussion section as follows:

"Furthermore, besides Th17 cells, innate lymphoid cells (ILCs) may also influence the stem cell niche as IL-23R+ ILCs have been reported to increase during inflammatory bowel disease and are capable of inducing colitis \[Baker et al., 2015; Geremia et al., 2011\]."

miR-34a knockout increased IL-23R expression in CD4^+^ T cells from uninfected animals (Figure 3---figure supplement 4A).

> • The authors test a role for stat3 in their model and claim that IL-17A activates stat3. Since IL17R\'s are known to signal through NF-κB, are these receptors also activating stat3 or is this a secondary effect of a downstream cytokine (for example IL-6 or IL-24) being produced?

We treated the colon organoids with 20μM Stattic along with different amount of IL-17A (2ng, 4ng and 8ng). Stattic alone significantly suppressed colon organoids growth and pSTAT3 activity. 2ng IL-17A could abrogate Stattic effect, while 4ng IL-17A could rescue colon organoids growth and pSTAT3 activity and 8ng IL-17A further enhanced colon organoids growth and pSTAT3 activity (Figure 4---figure supplement 7). Therefore, we think pSTAT3 activity is required to maintain colon organoids growth and IL-17 stimulation promotes organoids survival at least partially through pSTAT3 activity. We included the results in the revised manuscript.

As the reviewer mentioned, IL-17A/IL-17RA could enhance NF-κB signaling and upregulate IL6 expression which induces stat3 activation (\[3\]). In our study, both IL-17RA and IL-17RD are important for colon organoids growth. It is not clear whether IL-17/IL-17RA/IL-17RD directly activate stat3. However, we think it is likely NF-κB plays an important role in stat3 activation and colon organoids growth. We have added the following discussion to our revised manuscript: "IL-17A/IL-17RA could enhance NF-~κ~B signaling and upregulate IL-6 expression, which induces stat3 activation \[Wang et al., 2014\]. Therefore, NF-~κ~B may play an important role in the epithelial response to IL-17 stimulation."

> • What is the level of epithelial IL17RD expression in mir34aKO animals?

Loss of miR-34a increased IL-17RD expression according to western blot (Figure 3---figure supplement 4B).

> • Does treatment of infected mir-34a KO with anti-IL17A abrogate pathology and tumorigenesis?

We had anticipated this important question and were in the middle of this experiment when we submitted our first version. After infection, we treated the mice with anti-IL17 neutralizing antibody in the first 2 months, stopped treatment in the next 4 months, and sacrificed the mice at the end of month 6 post infection. The anti-IL17 treatment suppressed tumorigenesis (Figure 7JL), consistent with its effect on suppressing stem cell proliferation (Figure 7G-I). This result has been added to the revised manuscript.

> Reviewer \#3:
>
> \[...\] The manuscript is clearly written, the experiments are well described, and their results are largely consistent with the model proposed by the authors. Major strengths include the use of genetically engineered mice harboring targeted deletion of miR-34a and the use of intestinal organoids derived from these mice to explore the mechanisms through which miR-34a affects intestinal tumorigenesis and inflammation.
>
> Despite these major strengths, the manuscript has a few weaknesses that in my opinion need to be addressed. More specifically:
>
> 1\) One of the central claims of the authors is that loss of miR-34a leads to high incidence of colon cancers in Citrobacterium-infected mice. This claim is not adequately supported by the evidence presented in the manuscript. The only analysis provided in addition to the statement that 11 out of 20 mice developed tumors, are a single H&E staining (Figure 1A) and a single macroscopic image of a dissected colon (Figure 1B). Given the importance of this claim much more details should be provided. In particular, the authors should include a detailed histopathologic characterization of the lesions by an experience animal pathologist. This should be corroborated by low and high magnification images, immunostaining for β catenin, and histologic grading. Additional key questions that should be addressed include: Are the tumors invasive/metastatic? Are they adenocarcinomas or adenomas? Are they APC mutant? The pro-tumorigenic effect of miR-34 loss in this context is a major novelty of the manuscript, and therefore I believe these are important details that need to be included to support and better define the claim.

We completely agree with reviewer that a detailed histopathologic characterization is needed. In fact, reviewer 1 has raised similar concerns (see his question 1). Dr. Jeffrey Everitt, a board certified veterinary pathologist with extensive murine tumor experience, reviewed whole slide scanning of H&E stained colon sections from day 11, month 2, 4, and 6 post infection. His review confirmed that colon tumorigenesis and progression in the infected miR-34a -/- KO mice was histologically similar to those noted in other murine colon carcinogenesis models \[1\] (Figure 1A and Figure 1---figure supplement 1A). Immunostaining for β-catenin is consistent with neoplastic progression (Figure 1A).

In detail, histopathological changes of pre-neoplasia and neoplasia were limited to the miR 34a -/- genotype and were first noted at the four-month time point. Microscopic sections from wild type control mice were free of dysplastic and neoplastic changes at four-month (0/2) and six-month time points (0/20) following infection. In miR34a -/- mice no dysplasia or early neoplasia was present at a two-month time point (0/4), whereas at four months half the animals (2/4) had dysplastic change microscopically. At the six month time point (11/20) miR-34a-/- mice had microscopic changes ranging from dysplasia (2/20), to adenoma (7/20), to adenocarcinoma (2/20). The tumors were considered well-differentiated. Interestingly, the animal with a colonic adenocarcinoma in the distal colon also had a squamous cell carcinoma of the rectum.

The β-catenin IHC shows that dysplastic and neoplastic changes were characterized by strong intracytoplasmic staining and occasional cells with nuclear staining (Figure 1A).

We checked liver and lung of the infected miR-34a-/- mice with colon tumors. No metastasis was found in liver and lung, the most frequency metastatic organs for colon tumors (Figure 1---figure supplement 1B, C).

We checked APC mutation on saved tumors. We designed primers to amplify three most APC mutation regions in mouse colon cancer \[4-7\]. DNA sequencing showed the two regions were not mutated in the miR-34a-/- tumors (Figure 1---figure supplement 2).

> 2\) A more detailed characterization of the dynamic of inflammation in response to Citrobacterium infection in miR-34a wt and mutant mice should be provided. The authors only show the consequences at 11 days and at 6 months (Figure 1A), but it would be important to know what the intestine looks at intermediate time points. Does a state of chronic inflammation and intestinal stem cell hyper-proliferation develop in the miR-34a-null mice that would explain the increased tumor incidence at later time points?

We analyzed the colon cancer progression on 11 days, 2 month, 4 months and 6 months after *Citrobacterium* infection. Images from all four time points have been included in the revised manuscript (Figure 1A and Figure 1---figure supplement 1A).

We agree with the reviewer that a state of chronic inflammation and stem cell hyper-proliferation explains the increased tumor incidence. In miR34a-/- mice, at four months half the animals (2/4) had inflammation-induced dysplastic change and at six months, half the animals (11/20) formed tumors. According to the pathologist: "the earliest dysplastic changes are noted in deep reaches of crypts that are within inflamed ulcerated colonic mucosa in several of the sections where the diffuse inflammation of the *Citrobacter* has subsided and focal long-standing inflammation has set up due to ulceration of the surface. Further links the role of inflammation and carcinogenesis."

> 3\) Another essential aspect that needs to be addressed concerns the expression dynamic of miR-34a in the intestinal epithelium and in CD4^+^ cells undergoing Th17 differentiation. Knowing the relative expression levels of miR-34a, and how they change in response to Citrobacterium infection is essential to assess the plausibility of the proposed mechanism.

We infected mice with *Citrobacter* and collected CD4^+^ T cells and colon epithelial cells on day 7, day 14 and day 21 post-infection, followed by RT-qPCR measurements. miR-34a expression levels were upregulated in both CD4^+^ T cells and colon epithelial cells after infection (Figure 5---figure supplement 9C, D).

> 4\) The authors propose that miR-34a directly targets IL17RD, IL23R, and CCL22 by binding to their respective 3\'UTRs. In support of this hypothesis they present data that luciferase reporters containing the wt or mutant 3\'UTR are differentially sensitive to miR-34a overexpression. While this is a reasonable idea, it is important to recognize that in these experiments the ectopically expressed miRNA achieves levels that are often hundred folds greater than their physiologic levels. A more conclusive and elegant experiment would be to use CRISPR-Cas9 to introduce a point mutation in the predicted binding site and show that this leads to upregulation of the gene product in mIR-34a wt, but not in miR-34a-null cells. This experiment should be relatively straightforward to perform to validate the IL17RD site in intestinal organoids derived from miR-34a wild type and mutant mice.

We cloned the gRNA:CAGAATGATGGCGGTGGCAG-TGG (sequence complementary to miR-34a binding site highlighted by red) into the vector pLentiCRISPR v2, and transfected the CRISPR/CAS9 vector into mouse colon organoids). DNA sequencing of single colonies confirmed successful deletion of miR-34a binding in the mouse IL-17RD 3\`UTR. Western blot showed that miR-34a binding site deletion increased IL-17RD expression in wildtype mouse organoids but not in miR-34a-/- organoids (Figure 5---figure supplement 8).

Unfortunately we could not find any PAM motif around the miR-34a binding site in the CCL22 3\`UTR (cagtgactgccacagtttgttggtat) or in the IL23R 3\`UTR (ataagtacactgccatgactccaggatg), so we were not able to mutate these two binding sites specifically.

> 5\) An additional reason I am not fully convinced that miR-34a targets these genes directly via the proposed sites is that none of the three 3\'UTR sites is conserved in the human genome. The authors unfortunately fail to discuss this important point in the manuscript, a point that is even more relevant since they suggest that miR-34a plays a similar mechanism in suppressing colon cancer formation in humans (Figure 7).

We thank the reviewer for this important question. The reviewer is correct that the 3\`UTR sites are not conserved between mouse and human. We validated miR-34a binding sites in human IL-17RD, CCL22 and IL-6R 3UTR, and the binding site sequences are different between human and mice.

We ectopically expressed miR-34a in SW480 cells, a human colon cancer cell line and Jurkat cells, a human lymphocyte cell line, then measured IL-17RD and CCL22 expression in SW480 cells and IL-23R in Jurkat cells. The results showed that miR-34a suppressed IL-17RD and CCL22 expression, but not IL-23R (Figure 7---figure supplement 12). We added this into the Discussion section.

Interestingly, RNA-seq suggested by reviewer 1 showed that IL-6R was upregulated in CD4^+^ T cells. The IL-6/IL-6R axis plays important roles in Th17 cell differentiation, similar to IL-23. We validated that miR-34a directly targets IL6R in mouse CD4^+^ T cells, which suggests that miR34a targets both IL-6R and IL-23R to modulate mouse Th17 cell differentiation (Figure 3). We hypothesized that in human, miR-34a may modulate Th17 differentiation by targeting IL-6R alone. Indeed, ectopic miR-34a expression upregulated IL-6R expression in Jurkat cells (Figure 7---figure supplement 12).

We then checked the miR-34a binding sites in the 3\`UTRs of the human genes using miRanda and RNA22. Luciferase reporter assay showed that miR-34a directly binds to its putative binding sites in human IL-6R, CCL22, and IL-17RD 3\`UTRs, but not in the human IL-23R 3\`UTR (Figure 7---figure supplement 12).

Collectively, in mice miR-34a targets IL-6R and IL-23R simultaneously to regulate Th17 differentiation, and target CCL22 and IL-17RD in epithelial cells (Figure 8). In human, miR-34a only targets IL-6R but not IL-23R in T cells, and still targets CCL22 and IL-17RD in epithelial cells. We thank the reviewers' thoughtful questions, which has helped us reveal the role of IL-6R in this process. This provides an insight that, although miR-34a targeting of IL-23R is not conserved between mice and human, its function of regulating Th17 differentiation is still conserved via targeting IL-6R. These experiments have greatly strengthened the relevance of our study to the human disease.

> 6\) Finally, the experiments described in Figure 6 using conditional deletion of miR-34a in the intestine with Lgr5-Cre-ER are elegant but difficult to interpret because the authors do not show how efficiently tamoxifen delivery lead to bi-allelic miR-34a deletion in the intestinal epithelium. Poor Cre-mediated recombination could be a simple explanation for the reduced tumor incidence. This should be addressed if the authors want to include this experiment in the manuscript.
>
> Another useful control would be to include a cohort of mice generated by transplanting the bone marrow from miR-34a-/- mice into tamoxifen-treated Lgr5-Cre-ER;miR-34a fl/fl recipients. If the model proposed by the authors is correct, these animals should display a tumor incidence in response to Citrobacterium infection analogous to what was observed in miR-34a-/- animals. I understand, however, that performing these experiments would be a major undertaking in terms of time and resources and I would not insist on having this latter experiment included in the revised paper.

We validated miR-34a deletion after tamoxifen treatment by genotyping, which has been included in the revised manuscript (Figure 6---figure supplement 10). We agree with the reviewer that it would be an elegant experiment to transplant bone marrow from miR-34a-/- mice into tamoxifen-treated Lgr5-Cre-ER / miR-34a fl/fl mice. However, because we do not have enough Lgr5-Cre-ER / miR-34a fl/fl mice on hand, we would have to breed them first, and the *Citrobacter* infection experiment will take more than 6 months to conclude, so this experiment will likely take at least a year to complete. We thank the reviewer for the understanding.
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\[Editors\' note: the author responses to the re-review follow.\]

> The reviewers overall found your manuscript to be substantially improved and in principle of interest to eLife readership. However, there are still several concerns, which in our view are significantly substantial that we feel will need addressing experimentally. Normally, we do not pursue with the process if we feel that it could take the authors more than 2 months to complete. However, given the enthusiasm for your paper, we are willing to leave this door open for you, and encourage you to address the issues below, add the experiments, revise the text and figures and resubmit. If you address these final issues, I can ensure a rapid turnaround, but please do not take our enthusiasm for your work as an acceptance of your manuscript. The issues below need to be dealt with in a satisfactory way.
>
> The main lingering issue centers on the quality of some of your data and the lack of appropriate controls, which call into question your interpretation. Specifically, you claim that the crypts of infected mir34ko animals are enriched for stem cells based on increased Lgr5 and Ascl2 expression. Without either lineage tracing the stem cells or some kind of functional assay, this claim is not substantiated. Differentiated cells could merely be up-regulating the expression of these stem cell markers. The title of your paper is not justified without these data.

We performed a functional assay by measuring organoid-forming efficiency (1, 2). Wildtype and miR-34a-/- mice were infected with *C. rodentium* for 2 months along with the uninfected control groups. The mouse colons were then collected for organoid culture. 1000 organoid cells from each condition were reseeded to measure the organoids-forming efficiency. Cells from *C. rodentium* infected miR-34a-/- mice had significantly higher organoid-forming efficiency and growth rates than the other groups (Figure 1F-G).

> An additional concern raised by reviewer 2 is that you claim that the 3\' UTR of IL23R and IL16R has a mir34a-binding site, in the absence of which there is more IL17 production from CD4 T cells that contributes to pathology. What are the absolute numbers of these pathological Th17 cells? It is difficult to claim there are more Th17 cells based on frequencies on a FACS plot. Were they acquired from the gut or draining lymph node? Other cell types also express IL23R, for example ILCs. What is their level of IL-17A expression? Further what is the level of IL23R expression in the mir34aKo animals?

We infected wildtype and miR-34a-/- mice with *C. rodentium* for 2 months and then measured the absolute numbers of Th17 (CD4^+^IL17+) cells in the mouse colons. According to the protocol established by Weigmann B, et. Al (3), the average Th17 cell numbers were 277, 313, 1163 and 3378 for uninfected wild-type, uninfected miR-34a-/-, infected wild-type and infected miR-34a-/- respectively (Figure 2B). The wild-type Th17 cell number is comparable with some previously published data (4), but fewer than other reports (5). The discrepancy (loss of cells) could be caused by the exact handling of cell isolation, Th17 staining, enzyme incubation time, and FACS analysis. Therefore the trend between the groups is probably more important.

The CD4^+^cells were acquired from the colon, not the draining lymph nodes. We have clarified this in the main text and figure legend.

Among the ILCs, ILC3 cells were reported to express IL17A 6). We infected wildtype and miR-34a-/- mice with *C. rodentium* for 2 months, then isolate ILC3 cells by FACS sorting using an established protocol including a FITC labeled anti-mouse lineage cocktail, APC labeled anti-mouse CD117 and APC-Cy7 labeled anti-mouse CD45 antibody (7). The number of ILC3 cells were similar in wildtype and miR-34a-/- mouse colons (Figure 2---figure supplement 1A). RT-qPCR showed similar IL-17A levels in wildtype and miR-34a-/- ILC3 cells (Figure 2---figure supplement 1B).

We measured IL23R expression in WT and miR-34a-/- CD4^+^ T cells (Figure 3---figure supplement 1).

> Of additional concern, your team has tested for a role for stat3 and claim that IL17A activates stat3. Since IL17R\'s are known to signal through NF-κB, are these receptors also activating stat3 or is this a secondary effect of a downstream cytokine (for example IL-19/20/ IL-24) being produced? Again, it is difficult to make this link without the underlying mechanisms or at least a possible discussion of one. Related to this, what is the level of epithelial IL17RD expression in mir34aKO animals? Does treatment of infected mir-34a KO with anti-IL17A abrogate pathology and tumorigenesis?

Western blot showed that IL17 activates NF-κB in addition to STAT3 (Figure 4H). Treating colon organoids with an NF-κB inhibitor, BAY 11-7082, abrogated IL17-induced STAT3 phosphorylation and organoids growth (Figure 4H-J). Therefore, as the reviewer suggested, IL17 seems to activate STAT3 through NF-κB. We thank the reviewer for this suggestion.

Loss of miR-34a increased IL-17RD expression according to western blot (Figure 3---figure supplement 1).

We had anticipated the important question of anti-IL17A treatment and were in the middle of this experiment when we submitted our first version. After infection, we treated the mice with anti-IL17 neutralizing antibody in the first 2 months, stopped treatment in the next 4 months, and sacrificed the mice at the end of month 6 post infection. The anti-IL17 treatment suppressed tumorigenesis (Figure 6J-L).

> In your Lgr5-GFP-CreER; mIR34a fl/fl mouse model, how are the mRNA or protein levels of proposed mIR34a downstream targets affected? CCL22, IL17 etc. (Figure 6A). Figure 6D is lacking the ko\>ko and WT\>WT BM chimera control. It is difficult to interpret the use of WT controls, which have not undergone irradiation (a treatment known to affect the intestinal compartment).

We performed western blot for IL6R, IL23R, CCL22 and IL17RD in the Lgr5-GFP-CreER; mIR34a fl/fl mouse model. The miR-34a conditional knockout did not affect IL6R and IL23R expression in CD4^+^ T cells, but increased CCL22 and IL17RD expression in the colon epithelium (Figure 3---figure supplement 1E-H).

We agree that control experiments are important and we should have thought of them. However, they took more than 6 months to complete. Following the feedback from the editor and reviewers, we discussed the limitation of this experiment and clarified that we are unable to make conclusions about radio resistant cell types without the control chimera.

> Finally, reviewer 3 points out that the volcano plots shown in the supplementary figure should be complemented by including cumulative distribution (cdf) plots with logFC on the x axis comparing predicted miR34a targets to the rest of the transcriptome. These plots should show preferential derepression of the miR-34a targets (i.e. a shift to the right of the cdf plot compared to background). These are standard plots in the miRNA field and the reason for asking to include them has to do with the initial concerns raised regarding the absolute levels of miR-34a in these tissues. Demonstrating a signal attributable to miR-34a loss in the cdf plots would be conclusive evidence that the levels of miR-34a in these tissues are high enough to cause substantial target repression.

We thank the reviewer's suggestion and followed previous examples (8, 9) to add the cumulative distribution plot (Figure 3 ---figure supplement 4D).
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\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Reviewer \#2:
>
> I have one comment that can be addressed textually.
>
> In Figure 2---figure supplement 1 the authors claim to evaluate ILC3 based on CD117+ CD45+ cells. This is in no way a specific straining strategy for ILC3 and the authors should revise their claims of ILC3s not being effected in their system based on this rather rudimentary analysis.

We thank reviewer 2 for his/her in-depth knowledge on ILC3. We have revised the relevant sentence in the manuscript text as follows:

"In the infected colon, miR-34a deletion did not significantly increase the number or IL-17 expression level of lineage(CD3e/Ly-6G/Ly-6C/CD11b/CD45R/B220/TER-119)-/CD117+/CD45+ cells, which contain a subset of ILC3 cells that may express IL-17 \[[Dong, 2008]{.ul}\] (Figure 2---figure supplement 3A, B). Nevertheless, more markers will be needed to distinguish ILC3 and its subtypes specifically."

We have also revised the legend for Figure 2---figure supplement 3A accordingly:

"FACS plots based on CD117 and CD45 markers performed on lineage- cell populations isolated from colons of *C. rodentium-*infected wild-type and miR-34a-/- mice."
